Published in Blood Weekly, April 27th, 1998
In an interview, Garry McGrotty, NMT, said the tiny Scottish company, which floated on the Alternative Investment Market a year ago, was building up a small sales team of around 10 people for the European market.
In North America, where NMT has been taking on industry giants like Becton Dickinson and Co., it has planned to market its product through a joint venture with Canadian-based Solar Pharmaceuticals. It has also been talking to a potential Japanese partner.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.